Novarad’s OpenSight AR receives FDA approval for Microsoft Hololens

Novarad’s OpenSight® Augmented Reality (AR) System became the first AR medical solution for Microsoft HoloLens cleared by the FDA, according to Novorad, when it received 510(k) clearance for use in pre-operative surgical planning. The solution’s patented virtual tool technology and integrated targeting system, lets doctors see the patient and into the patient simultaneously to more accurately plan surgery.

OpenSight augmented reality allows a much better understanding of anatomic relationships, the company says, because the images are co-localized to the patient. Pre-operative planning with OpenSight makes it possible to highlight relevant anatomy and critical structures to avoid, as well as positioning virtual tools and guidance systems to more accurately plan a surgical approach. Multiple headsets can be shared among users improving the training of less experienced residents and a teaching version of the software is also available that lets medical students perform virtual dissections on cadavers.

“This is transformative technology that will unite preoperative imaging with augmented reality to improve the precision, speed and safety of medical procedures,” says Dr. Wendell Gibby, Novarad CEO and co-creator of OpenSight. “This internal visualization can now be achieved without the surgeon ever making an incision, improving outcomes in a world of more precise medicine.”